GNS Healthcare (GNS), a leading precision medicine AI company, announced today an extension of their Series D funding round, bringing the amount raised to $28 million, thanks to an investment from Merck Global Health Innovation Fund (GHI).
|
CAMBRIDGE, Mass., Jan. 7, 2020 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine AI company, announced today an extension of their Series D funding round, bringing the amount raised to $28 million, thanks to an investment from Merck Global Health Innovation Fund (GHI). The extension brings the total capital raised to date to $66 million.
"We are excited to have Merck GHI invest in this next phase of our growth strategy," said Colin Hill, Chairman, CEO and Co-Founder of GNS Healthcare. "This funding will enable us to leverage our in silico cancer patients across clinical development and market access to drive the discovery of responding subpopulations, conduct in silico combination therapy optimization and line of therapy change." With almost 50 peer-reviewed publications and abstracts, the GNS REFS platform is the most validated AI platform in the industry for identifying drivers of patient response to therapeutics and other interventions across oncology, immunology, cardio-metabolic diseases and neurological disorders. GNS works with leading biopharma companies and health plans to deploy in silico patients that precisely match therapeutics, procedures and care management interventions to individuals to accelerate the development and commercialization of new drugs and their application in the real-world to improve health outcomes and lower the total cost of care. About Merck Global Health Innovation Fund About GNS Healthcare GNS Media Contact:
SOURCE GNS Healthcare |
View original content to download multimedia:
